SYSMEX CORP.UNSP.ADR 1/2 - Asset Resilience Ratio
SYSMEX CORP.UNSP.ADR 1/2 (0YX0) has an Asset Resilience Ratio of 0.05% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of SYSMEX CORP.UNSP.ADR 1/2 to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how SYSMEX CORP.UNSP.ADR 1/2's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of SYSMEX CORP.UNSP.ADR 1/2.
Liquid Assets Composition Over Time
This chart breaks down SYSMEX CORP.UNSP.ADR 1/2's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 0YX0 total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €351.00 Million | 0.05% |
| Total Liquid Assets | €351.00 Million | 0.05% |
Asset Resilience Insights
- Limited Liquidity: SYSMEX CORP.UNSP.ADR 1/2 maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SYSMEX CORP.UNSP.ADR 1/2 Industry Peers by Asset Resilience Ratio
Compare SYSMEX CORP.UNSP.ADR 1/2's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
COPLAND ROAD CAPITAL NEW
F:A2P |
Medical Devices | 0.00% |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298 |
Medical Devices | 2.82% |
|
Shanghai Kinetic Medical Co
SHE:300326 |
Medical Devices | 28.89% |
Annual Asset Resilience Ratio for SYSMEX CORP.UNSP.ADR 1/2 (2022–2025)
The table below shows the annual Asset Resilience Ratio data for SYSMEX CORP.UNSP.ADR 1/2.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.10% | €654.00 Million ≈ $764.59 Million |
€665.27 Billion ≈ $777.77 Billion |
-0.11pp |
| 2024-03-31 | 0.21% | €1.31 Billion ≈ $1.53 Billion |
€618.92 Billion ≈ $723.58 Billion |
+0.05pp |
| 2023-03-31 | 0.16% | €875.00 Million ≈ $1.02 Billion |
€531.07 Billion ≈ $620.88 Billion |
-0.14pp |
| 2022-03-31 | 0.31% | €1.50 Billion ≈ $1.75 Billion |
€483.71 Billion ≈ $565.50 Billion |
-- |
About SYSMEX CORP.UNSP.ADR 1/2
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematol… Read more